We are live on ! Find out more
KERX

Keryx Biopharmaceuticals Inc
KERX

Delisted

KERX was delisted on the 12th of December, 2018.

157 hedge funds and large institutions have $1.19B invested in Keryx Biopharmaceuticals Inc in 2015 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 73 increasing their positions, 28 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

161% more repeat investments, than reductions

Existing positions increased: 73 | Existing positions reduced: 28

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

46% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 24

10% more capital invested

Capital invested by funds: $1.08B → $1.19B (+$107M)

7% more funds holding

Funds holding: 147157 (+10)

14% less call options, than puts

Call options by funds: $10.5M | Put options by funds: $12.2M

Holders
157
Holders Change
+10
Holders Change %
+6.8%
% of All Funds
4.18%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.08%
New
35
Increased
73
Reduced
28
Closed
24
Calls
$10.5M
Puts
$12.2M
Net Calls
-$1.72M
Net Calls Change
-$5.57M
Name Holding Trade Value Shares
Change
Change in
Stake
BG
101
BlackRock Group
United Kingdom
$326K +$61.7K +4,799 +23%
Barclays
102
Barclays
United Kingdom
$322K +$52.7K +4,101 +18%
T. Rowe Price Associates
103
T. Rowe Price Associates
Maryland
$302K -$13.9K -1,080 -4%
VKH
104
Virtu KCG Holdings
New York
$298K +$74.4K +5,791 +33%
M&T Bank
105
M&T Bank
New York
$267K -$5.41K -421 -2%
SM
106
Southport Management
Wyoming
$255K +$257K +20,000 New
RJA
107
Raymond James & Associates
Florida
$250K +$28.7K +2,235 +13%
ProShare Advisors
108
ProShare Advisors
Maryland
$249K -$1.27K -99 -0.5%
SKK
109
Shepherd Kaplan Krochuk
Massachusetts
$239K +$79.1K +6,153 +49%
Principal Financial Group
110
Principal Financial Group
Iowa
$238K +$51.1K +3,977 +27%
Victory Capital Management
111
Victory Capital Management
Texas
$226K -$5.17M -401,825 -96%
VAM
112
Visium Asset Management
New York
$221K +$223K +17,380 New
Legal & General Group
113
Legal & General Group
United Kingdom
$207K +$31.6K +2,461 +18%
SM
114
Sabby Management
Florida
$188K +$190K +14,758 New
Envestnet Asset Management
115
Envestnet Asset Management
Illinois
$187K +$188K +14,657 New
NIT
116
NumerixS Investment Technologies
British Columbia, Canada
$187K +$189K +14,700 New
QT
117
Quantbot Technologies
New York
$159K -$59.2K -4,605 -27%
Creative Planning
118
Creative Planning
Kansas
$159K -$27K -2,100 -14%
D.E. Shaw & Co
119
D.E. Shaw & Co
New York
$152K -$986K -76,664 -87%
Royal Bank of Canada
120
Royal Bank of Canada
Ontario, Canada
$141K -$262K -20,352 -65%
Prudential Financial
121
Prudential Financial
New Jersey
$135K +$6.43K +500 +5%
AG
122
Aperio Group
California
$134K -$71.2K -5,535 -34%
AIM
123
Advantage Investment Management
Iowa
$132K +$134K +10,400 New
AB
124
Amalgamated Bank
New York
$129K +$130K +10,147 New
Canada Life
125
Canada Life
Manitoba, Canada
$127K

KERX Hedge Fund Activity: Q1 2015 in Review

157 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Keryx Biopharmaceuticals Inc (KERX) for Q1 2015, worth a combined $1.19B — up 9.9% from $1.08B a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new KERX positions and 24 closed out — a net gain of 11 holders — while 73 added to existing stakes and 28 trimmed.

The largest buyer was Baupost Group, adding an estimated $52.5M. The largest seller was Eagle Asset Management, cutting an estimated $10.4M.

  • 157 institutional investors held Keryx Biopharmaceuticals Inc (KERX) as of Q1 2015, up from 147 in Q4 2014.
  • Funds reported $1.19B of Keryx Biopharmaceuticals Inc stock for Q1 2015, up 9.9% quarter-over-quarter.
  • 35 funds opened new Keryx Biopharmaceuticals Inc positions in Q1 2015 and 24 closed out, a net change of +11 holders.
  • The largest Keryx Biopharmaceuticals Inc buyer in Q1 2015 was Baupost Group, an estimated $52.5M added.
  • The largest Keryx Biopharmaceuticals Inc seller in Q1 2015 was Eagle Asset Management, an estimated $10.4M sold.

Based on aggregated 13F filings for Q1 2015.